Unknown

Dataset Information

0

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.


ABSTRACT: OBJECTIVE:To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with active moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapy. METHODS:Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co-primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 24, and change from baseline in the Health Assessment Questionnaire disability index (HAQ DI) at week 12. Each sarilumab dose was evaluated against placebo; differences between the 2 sarilumab doses were not assessed. RESULTS:The baseline characteristics of the treatment groups were similar. The ACR20 response rate at week 24 was significantly higher with sarilumab 150 mg and sarilumab 200 mg every 2 weeks compared with placebo (55.8%, 60.9%, and 33.7%, respectively; P?

SUBMITTER: Fleischmann R 

PROVIDER: S-EPMC6207906 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.

Fleischmann Roy R   van Adelsberg Janet J   Lin Yong Y   Castelar-Pinheiro Geraldo da Rocha GD   Brzezicki Jan J   Hrycaj Pawel P   Graham Neil M H NM   van Hoogstraten Hubert H   Bauer Deborah D   Burmester Gerd R GR  

Arthritis & rheumatology (Hoboken, N.J.) 20170201 2


<h4>Objective</h4>To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with active moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapy.<h4>Methods</h4>Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co-primar  ...[more]

Similar Datasets

| S-EPMC6702535 | biostudies-literature
| S-EPMC6824353 | biostudies-literature
| S-EPMC6824456 | biostudies-literature
| S-EPMC5353328 | biostudies-literature
| S-EPMC4112169 | biostudies-literature
| S-EPMC8174161 | biostudies-literature
| S-EPMC6135452 | biostudies-other
| S-EPMC10397978 | biostudies-literature
| S-EPMC4414700 | biostudies-literature
| S-EPMC6902348 | biostudies-literature